All research peptides supplied by OPTMZ Peptides are intended strictly for laboratory research applications and are not designed for medical use. These materials are not approved by the U.S. Food and Drug Administration (FDA) to diagnose, treat, cure, or prevent any disease. By purchasing, the buyer confirms use strictly for scientific research purposes and not for human or animal consumption.
Product Overview
Ipamorelin is a synthetic pentapeptide growth hormone secretagogue investigated in controlled laboratory and clinical research for its interaction with the growth hormone secretagogue receptor, also known as the ghrelin receptor (GHSR/GHS-R1a).
Ipamorelin has the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂ and was developed as a selective growth hormone secretagogue. Experimental studies have examined its effects on GH release, pituitary signaling, ghrelin-receptor biology, pharmacokinetics, and gastrointestinal motility.
Ipamorelin is a synthetic pentapeptide growth hormone secretagogue composed of the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂. Its structure incorporates non-natural residues, including α-aminoisobutyric acid (Aib), D-2-naphthylalanine, and D-phenylalanine, and it terminates in a lysinamide. The peptide was developed for selective interaction with growth hormone secretagogue receptor signaling.
170851-70-4 This CAS number is both reported by PubChem and confirmed on the actual OPTMZ laboratory COA.
Amino Acid Sequence
Aib-His-D-2-Nal-D-Phe-Lys-NH₂
The sequence is reported in the original pharmacology literature describing Ipamorelin.
Primary Molecular Target
Growth Hormone Secretagogue Receptor (GHSR / GHS-R1a), also known as the ghrelin receptor The NCI describes Ipamorelin as a ghrelin mimetic that binds the ghrelin/GH-secretagogue receptor.
Experimental Applications
GHSR receptor signaling studies
Growth hormone release research
Pituitary signaling studies
Ghrelin-receptor pharmacology
Growth hormone secretagogue research
GH pharmacokinetic/pharmacodynamic studies
Gastrointestinal motility research
Gastric-emptying models
Somatotroph research
Peptide structure-function analysis
Experimental Systems
GHSR receptor signaling studies
Growth hormone release research
Pituitary signaling studies
Ghrelin-receptor pharmacology
Growth hormone secretagogue research
GH pharmacokinetic/pharmacodynamic studies
Gastrointestinal motility research
Gastric-emptying models
Somatotroph research
Peptide structure-function analysis
For the actual OPTMZ lot, Krause Analytical specifically performed HPLC-UV-MS analysis and USP <85> endotoxin testing.
Mechanism / Research Context
Ipamorelin is a selective growth hormone secretagogue that acts through the growth hormone secretagogue receptor, also known as the ghrelin receptor or GHS-R1a.
Activation of GHSR initiates intracellular signaling associated with pituitary GH release. This mechanism is distinct from that of GHRH analogs, which act through the GHRH receptor. The original Ipamorelin pharmacology study characterized the compound as a pentapeptide with potent GH-releasing activity in vitro and in vivo.
Human pharmacokinetic/pharmacodynamic research found a dose-proportional disposition profile and a single episode of GH release after administration, with the GH response peaking and subsequently declining.
Additional preclinical research has examined Ipamorelin as a ghrelin-receptor agonist in gastrointestinal motility and postoperative ileus models.
Evidence Level
Clinical Research Ipamorelin has been evaluated in controlled human pharmacokinetic/pharmacodynamic studies in addition to substantial preclinical research. This classification refers to the existence of human research, not FDA approval or established therapeutic efficacy.
Research References
Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. PMID: 9849822. Gobburu JVS, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999. PMID: 10496658. Venkova K, et al. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. J Pharmacol Exp Ther. 2009. PMID: 19289567. Jiménez-Reina L, et al. Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro. Histol Histopathol. 2002. PMID: 12168778. PubChem CID 9831659: Ipamorelin structural and molecular information.
Analytical Characterization
ndependent analytical testing of OPTMZ Peptides Ipamorelin 10 mg, batch/lot 2026/02, by Krause Analytical reported:
Chromatographic Purity: >99.9%
Ipamorelin Content: 9.80 mg
Label Claim: 10 mg
Percent of Label: 98.0%
Identity: Mass spectral match confirmed
CAS Number: 170851-70-4
Analysis Method: HPLC-UV-MS
Endotoxins: <0.5 EU/mL
Endotoxin Method: USP <85>
Lab Number: 205077
Project: 145211
Date Received: April 28, 2026
Report Issued: May 13, 2026
The report specifies that analytical values are reported on a per-vial basis unless otherwise noted.
All research peptides supplied by OPTMZ Peptides are intended exclusively for laboratory research applications and are not designed for medical use. These products are not approved by the U.S. Food and Drug Administration (FDA) to diagnose, treat, cure, or prevent any disease. By purchasing, the buyer confirms use strictly for scientific research purposes and not for human or animal consumption.
Product Overview
Ipamorelin is a synthetic research peptide classified as a selective ghrelin receptor (GHS-R1a) agonist. It is examined in controlled laboratory environments for its interaction with growth hormone–related signaling pathways and endocrine system models.
Technical Specifications
CAS Number: 170851-70-4
Molecular Formula: C₃₈H₄₉N₉O₅
Molecular Weight: 711.9 g/mol
PubChem ID: 9831659
Pituitary signaling
Growth hormone secretagogue pharmacology
Ghrelin-mimetic research
Pharmacokinetic/pharmacodynamic modeling
Gastrointestinal motility
Gastric emptying
Somatotroph signaling
Peptide structure-function studies
The original pharmacology literature describes Ipamorelin as a selective growth hormone secretagogue with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂.
The National Cancer Institute describes it as a ghrelin mimetic that binds the ghrelin/growth hormone secretagogue receptor and stimulates GH release.
Ipamorelin has also been evaluated in human pharmacokinetic/pharmacodynamic research, where investigators characterized its disposition and the time course of GH stimulation.
These findings describe research observations and do not establish approved therapeutic use of the research product supplied here.
Research Application Scope
Ipamorelin is relevant to controlled experimental investigations involving ghrelin receptor biology, GH secretion pathways, pituitary signaling, endocrine pharmacology, and peptide-receptor interactions.
Because it acts through GHSR rather than GHRHR, Ipamorelin is mechanistically distinct from GHRH analogs such as CJC-1295. This makes it useful in comparative research examining different receptor pathways involved in GH secretion.
Use Statement
For laboratory research use only. Intended strictly for in vitro and controlled experimental research applications.
Disclaimer
All products currently listed on this site are for research purposes ONLY.
Reviews
There are no reviews yet.